Activation of 5-HT3 receptors leads to altered responses 6 months after MDMA treatment.
The recreational drug "Ecstasy" [3,4-methylenedioxymethamphetamine (MDMA)] has a well-characterised neurotoxic effect on the 5-hydroxytryptamine (5-HT) neurons in animals. Despite intensive studies, the long-term functional consequencies of the 5-HT neurodegeneration remains elusive. The aim of this study was to investigate whether any alteration of 5-hydroxytryptamine-3 (5-HT(3)) receptor functions on the sleep-wake cycle, motor activity, and quantitative EEG could be detected 6 months after a single dose of 15 mg/kg of MDMA. The selective 5-HT(3) receptor agonist m-chlorophenylbiguanide (mCPBG; 1 mg/kg, i.p.) or vehicle was administered to freely moving rats pre-treated with MDMA (15 mg/kg, i.p.) or vehicle 6 months earlier. Polysomnographic and motor activity recordings were performed. Active wake (AW), passive wake (PW), light slow wave sleep (SWS-1), deep slow wave sleep (SWS-2), and paradoxical sleep were classified. In addition, EEG power spectra were calculated for the second hour after mCPBG treatment for each stage. AW increased and SWS-1 decreased in the second hour after mCPBG treatment in control animals. mCPBG caused significant changes in the EEG power in states with cortical activation (AW, PW, paradoxical sleep). In addition, mCPBG had a biphasic effect on hippocampal theta power in AW with a decrease in 7 Hz and a stage-selective increase in the upper range (8-9 Hz). Effects of mCPBG on the time spent in AW and SWS-1 were eliminated or reduced in MDMA-treated animals. In addition, mCPBG did not increase the upper theta power of AW in rats pre-treated with MDMA. These data suggest long-term changes in 5-HT(3) receptor function after MDMA.
Gyongyosi
Norbert
N
Department of Pharmacodynamics, Semmelweis University, Budapest, Hungary. norbert.gyongyosi@eok.sote.hu
Balogh
Brigitta
B
Katai
Zita
Z
Molnar
Eszter
E
Laufer
Rudolf
R
Tekes
Kornelia
K
Bagdy
Gyorgy
G
D000818:Animals; D001645:Biguanides / Q000494:pharmacology; D001921:Brain / Q000187:drug effects* / Q000502:physiology; D002940:Circadian Rhythm / Q000187:drug effects* / Q000502:physiology; D004569:Electroencephalography; D006624:Hippocampus / Q000187:drug effects / Q000502:physiology; D008297:Male; D009043:Motor Activity / Q000187:drug effects* / Q000502:physiology; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage / Q000494:pharmacology*; D017286:Polysomnography; D011897:Random Allocation; D051381:Rats; D044406:Receptors, Serotonin, 5-HT3 / Q000378:metabolism*; D058827:Serotonin 5-HT3 Receptor Agonists; D018490:Serotonin Agents / Q000008:administration & dosage / Q000494:pharmacology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology; D012890:Sleep / Q000187:drug effects / Q000502:physiology; D012894:Sleep Stages / Q000187:drug effects / Q000502:physiology; D013826:Theta Rhythm; D013997:Time Factors; D014851:Wakefulness / Q000187:drug effects / Q000502:physiology
D001645:Biguanides; D044406:Receptors, Serotonin, 5-HT3; D058827:Serotonin 5-HT3 Receptor Agonists; D018490:Serotonin Agents; D017366:Serotonin Receptor Agonists; C065734:1-(3-chlorophenyl)biguanide; D018817:N-Methyl-3,4-methylenedioxyamphetamine